The prognosis of follicular lymphomas (FL) is heterogeneous and numerous treatments may be proposed. A validated prognostic index (PI) would help in evaluating and choosing these treatments. Characteristics at diagnosis were collected from 4167 patients with FL diagnosed between 1985 and 1992. Univariate and multivariate analyses were used to propose a PI. This index was then tested on 919 patients. Five adverse prognostic factors were selected: age (> 60 years vs < or = 60 years), Ann Arbor stage (III-IV vs I-II), hemoglobin level (< 120 g/L vs > or = 120 g/L), number of nodal areas (> 4 vs < or = 4), and serum LDH level (above normal vs normal or below). Three risk groups were defined: low risk (0-1 adverse factor, 36% of patients), intermediate risk (2 factors, 37% of patients, hazard ratio [HR] of 2.3), and poor risk (> or = 3 adverse factors, 27% of patients, HR = 4.3). This Follicular Lymphoma International Prognostic Index (FLIPI) appeared more discriminant than the International Prognostic Index proposed for aggressive non-Hodgkin lymphomas. Results were very similar in the confirmation group. The FLIPI may be used for improving treatment choices, comparing clinical trials, and designing studies to evaluate new treatments.
|Data di pubblicazione:||2004|
|Titolo:||Follicular lymphoma international prognostic index.|
|Autori:||SOLAL CELIGNY, P; Roy, P; Colombat, P; White, J; Armitage, Jo; ARRANZ SAEZ, R; Au, Wy; Bellei, Monica; Brice, P; Caballero, D; Coiffier, B; CONDE GARCIA, E; Doyen, C; Federico, Massimo; Fisher, Ri; GARCIA CONDE, Jf; Guglielmi, C; Hagenbeek, A; Haioun, C; Leblanc, M; Lister, At; LOPEZ GUILLERMO, A; Mclaughlin, P; Milpied, N; Morel, P; Mounier, N; Proctor, Sj; Rohatiner, A; Smith, P; Soubeyran, P; Tilly, H; Vitolo, U; Zinzani, Pl; Zucca, E; Montserrat, E.|
|Digital Object Identifier (DOI):||10.1182/blood-2003-12-4434|
|Appare nelle tipologie:||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris